A groundbreaking study has emerged from the laboratories of The University of Texas M.D. Anderson Cancer Center and the University of California San Diego’s Division of Gynecologic Oncology, unveiling a novel approach to detecting structural variants (SVs) in high grade serous ovarian cancer (HGSOC) through tumor-informed liquid biopsy. Published in the March 2026 issue of Oncoscience, this research offers a promising avenue for enhancing the sensitivity and specificity of monitoring disease progression and therapeutic response in ovarian cancer patients, a notoriously lethal gynecologic malignancy.
Ovarian cancer, particularly HGSOC, presents a formidable challenge due to its genomic complexity, characterized by extensive chromosomal rearrangements rather than predominantly single nucleotide variants (SNVs). Traditional circulating tumor DNA (ctDNA) assays typically focus on SNV detection, which may limit their efficacy in this context. Addressing this, the study introduces a sophisticated workflow that leverages whole-genome sequencing (WGS) of multisite tumor biopsies to identify patient-specific SV breakpoints, enabling highly personalized liquid biopsy assays.
The researchers deployed a meticulous pipeline where tumor tissue obtained from multiple anatomical sites within each patient underwent WGS to pinpoint breakpoints unique to each tumor’s structural rearrangements. These breakpoints then served as precise targets for designing custom primer and probe sets that span the junctions of structural variants. Employing digital droplet PCR (ddPCR), a highly sensitive and quantitative amplification technique, the team was able to detect these SVs in cell-free DNA (cfDNA) extracted from patient plasma, providing a non-invasive window into tumor dynamics.
Calibration and optimization efforts were conducted initially using synthetic cfDNA derived from ovarian cancer cell lines harboring known structural variants, ensuring assay robustness and reproducibility. The transition to clinical samples involved four patients diagnosed with HGSOC who underwent multisite biopsies alongside pre-treatment blood draws. The WGS data facilitated the design of 29 tumor-informed breakpoint assays, of which 15 were validated for tumor specificity, and nine generated measurable signals in plasma cfDNA, confirming the practical feasibility of this approach in a real-world setting.
One of the study’s notable achievements was the demonstration that ddPCR outperformed conventional real-time PCR in sensitivity when quantifying SV concentration in plasma. Because ddPCR partitions samples into thousands of droplets, each serving as an individual PCR reaction, it enables absolute quantification of mutant alleles, even when present at exceedingly low frequencies. This technological advantage is crucial for detecting minimal residual disease (MRD) and early relapse, which require exquisite assay sensitivity.
The data underscored the ability to detect multiple SV targets per patient, with copy numbers quantified per nanogram of cfDNA input. This precision measurement permits dynamic monitoring of tumor burden over time and may provide actionable insights into patient-specific responses to treatment. Importantly, germline white blood cell DNA and plasma from healthy controls served as critical negative controls, establishing the high specificity of the tumor-informed ddPCR assays and mitigating the risk of false positives from clonal hematopoiesis or background genetic noise.
However, the authors prudently recognize the pilot nature of their study, constrained by the small sample size and reliance on extensive tumor tissue biopsies of sufficient quality to call confident SV breakpoints. The necessity for individualized assay design based on WGS data imposes a longer turnaround time and higher costs compared to standardized off-the-shelf ctDNA panels that target common recurrent mutations. Despite these limitations, the strategy outlines a pathway by which personalized SV detection could complement or surpass existing mutation-based monitoring tools for HGSOC.
Future directions outlined in the study emphasize the imperative to validate the approach in larger patient cohorts with rigorous longitudinal sampling, to refine bioinformatics pipelines for accelerated SV calling, and to streamline assay design workflows for clinical adoption. Head-to-head comparisons with SNV-based tumor-informed liquid biopsy methodologies are also critical to delineate the relative advantages and clinical utility of each approach, especially in a disease setting dominated by complex structural rearrangements.
The promise of ddPCR-based SV assays lies in their potential to revolutionize the clinical management of high-grade serous ovarian cancer by enabling timely and sensitive detection of disease recurrence, minimal residual disease, and therapeutic response. Incorporating tumor-informed liquid biopsy into oncologic monitoring frameworks could transform surveillance paradigms, facilitating personalized patient care and potentially improving outcomes in a cancer type known for late diagnosis and therapeutic resistance.
In summary, this pioneering work bridges advanced genomics with precision molecular diagnostics, harnessing the specificity of tumor-informed SV identification and the sensitivity of ddPCR to forge a new frontier in ovarian cancer liquid biopsy. As the technology and methodology mature, it may become an indispensable tool in the oncologist’s arsenal for managing one of the deadliest forms of cancer with enhanced finesse and accuracy.
This study, led by Jian Li and corresponding author R. Tyler Hillman, represents a concerted effort in the evolving landscape of liquid biopsy technology, signifying a shift towards structural variant-centric cancer monitoring tailored to individual tumor biology. The open-access publication ensures that these insights are broadly accessible, encouraging further research and collaboration in the quest to improve cancer diagnostics and patient survival rates.
DOI: https://doi.org/10.18632/oncoscience.645
Correspondence: R. Tyler Hillman – tyhillman@health.ucsd.edu
Subject of Research: People
Article Title: Tumor-informed liquid biopsy detection of structural variants in high grade serous ovarian cancer
News Publication Date: 5-Mar-2026
Web References:
https://doi.org/10.18632/oncoscience.645
https://www.mdanderson.org/
https://obgyn.ucsd.edu/divisions/gynecologic-oncology.html
Image Credits: Copyright: © 2026 Li et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0).
Keywords: cancer, ovarian cancer, ctDNA, biomarker, liquid biopsy, structural variant
